Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02277613 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

A Phase 2 study, sponsored by Healios K.K..

Terminated
Registry status
Phase 2
Development phase
34
Enrollment target

NCT02277613 is a Phase 2 study that was terminated before completion, run by Healios K.K.. The registered enrollment target is 34 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02277613, a Phase 2 study, was terminated before completion, sponsored by Healios K.K..

TERMINATED
Registry status
Phase 2
Development phase
34 participants
Enrollment target

Study Summary

This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).

Interventions

  • OTHER Sham
  • BIOLOGICAL AMI MultiStem cells

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2015-12
Est. Completion 2020-01
Phase Phase 2

Sponsor

Healios K.K.

6 total trials

What the Registry Record Tells You About NCT02277613

The ClinicalTrials.gov registry entry for NCT02277613 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Healios K.K., which has 6 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.

NCT02277613 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02277613 about?

NCT02277613 is a clinical study titled "A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction". This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).

What is the current status of trial NCT02277613?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2015-12. Estimated completion is 2020-01.

What interventions are being tested in trial NCT02277613?

The interventions under investigation include: Sham (OTHER), AMI MultiStem cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT02277613?

This trial is sponsored by Healios K.K., which has 6 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.